Open AccessTopoisomerase Mutations Associated with In Vitro Selection of Resistance to Moxifloxacin in Streptococcus pneumoniae
Author(s) -
S. Houssaye,
Laurent Gutmann,
Emmanuelle Varon
Publication year - 2002
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.46.8.2712-2715.2002
Subject(s) - dna gyrase , moxifloxacin , topoisomerase iv , quinolone , streptococcus pneumoniae , mutation , biology , microbiology and biotechnology , topoisomerase , mutant , antibacterial agent , genetics , in vitro , antibiotics , gene , escherichia coli
We analyzed the frequencies of selection, the order of acquisition, and the mutations selected on moxifloxacin in two wild-type pneumococcal strains, R6 and 5714. The first selection step showed either a single GyrA mutation or no mutation in any of the quinolone resistance-determining regions. Second-step mutants selected had either a second mutation in ParC or in ParE. Moxifloxacin could belong to these fluoroquinolones, which preferentially target GyrA though probably acting equally through both gyrase and topoisomerase IV.